NASDAQ$TRML
Tourmaline Bio Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Tourmaline Bio reported Q1 2025 a net loss of $23.0M, diluted EPS of $(0.89).
For Q1 2025, Tourmaline Bio reported net loss was $23.0M, diluted EPS was $-0.89. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Net loss $23.0M.
- Diluted EPS $-0.89.
- MD&A highlights operating priorities, liquidity, and sector-specific risks.
Headline financials
Revenue & EPS history
Tourmaline Bio · Revenue · Quarterly
$0
Forward guidance
Management emphasizes path to profitability, liquidity, and cost discipline.
Tailwinds
- Operating initiatives and partnership milestones.
- Cash runway and restructuring where applicable.
Headwinds
- Operating losses and financing needs.
- Macro and competitive uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q1 2025
+0.7%
Avg return
Earnings day
-5.0%
Avg return
5 days after
+13.7%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+11.6%
Q4 2023
Best reaction
-9.7%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +3.8% | +3.1% | +122.3% | |
| Q1 2025 | +4.6% | +9.9% | +26.5% | |
| Q4 2024 | -2.8% | -4.8% | -1.4% | |
| Q3 2024 | +5.0% | -4.9% | -5.6% | |
| Q2 2024 | +2.0% | +4.6% | +12.2% | |
| Q1 2024 | -0.6% | -4.8% | +2.6% | |
| Q4 2023 | +11.6% | -38.1% | -60.9% | |
| Q3 2023 | -1.2% | — | — | |
| Q2 2023 | +1.3% | — | — | |
| Q1 2023 | -8.0% | — | — | |
| Q4 2022 | +2.8% | — | — | |
| Q3 2022 | +7.0% | — | — | |
| Q2 2022 | -9.7% | — | — | |
| Q1 2022 | +3.1% | — | — | |
| Q4 2021 | +4.6% | — | — | |
| Q3 2021 | -7.0% | — | — | |
| Q2 2021 | -5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro